이식 진단 시장 보고서 : 성분, 기술, 장기 유형, 용도, 최종사용자, 지역별(2024-2032년)

The global transplant diagnostics market size reached US$ 873.7 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,709.0 Million by 2032, exhibiting a growth rate (CAGR) of 7.5% during 2024-2032.

Transplant diagnostics are the basis for histocompatibility and immunogenetics of organ and hematopoietic stem cell transplantations. They assist healthcare professionals in determining the compatibility between potential organ donors and recipients. They increase the chances of organ survival while minimizing serious transplant complications. As a result, they are used in various disciplines, such as pathology, immunogenetics, infectious diseases, molecular diagnostics, therapeutic drug monitoring, and human leukocyte antigens (HLA) typing and monitoring.

Transplant Diagnostics Market Trends:

The growing prevalence of acute and chronic diseases on account of the increasing consumption of processed food products and the escalating number of individuals that smoke tobacco products and consume alcohol is causing a significant rise in the number of organ failure cases. This, in confluence with the growing number of blood donors, represents one of the primary factors driving the demand for transplant diagnostics worldwide to ensure donor-recipient compatibility and improve the quality of life of transplant patients. Moreover, as older people are more prone to health problems and organ failure, the rising geriatric population across the globe is contributing to market growth. The escalating number of severe road accidents or collisions is also influencing the demand for organ transplantation and its diagnostics. Apart from this, manufacturers are offering a comprehensive range of antibody detection products, laboratory instrumentation, and computer software. These products can be utilized to simplify and automate testing procedures and final test evaluations, which is creating a favorable market outlook. Furthermore, the increasing expenditure in the healthcare sector by governments of several countries is impelling the market growth. Furthermore, several healthcare firms are focusing on developing innovative, high-quality HLA products for clinical and research applications, which, in turn, is projected to drive the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global transplant diagnostics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on component, technology, organ type, application and end user.

Breakup by Component:

• Instrument and Equipment
• Reagent and Consumables
• Software and Services

Breakup by Technology:

• Non-Molecular Assay
  • Serological Assay
  • Mixed Lymphocyte Culture
• Molecular Assay
  • PC-based
  • Sequencing-based

Breakup by Organ Type:

• Kidney
• Liver
• Heart
• Lung
• Pancreas
• Others

Breakup by Application:

• Pre-Transplant Diagnostics
• Post-Transplant Diagnostics

Breakup by End User:

• Hospitals and Transplant Centers
• Research Laboratories and Academic Institutes
• Commercial Service Providers

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton Dickinson and Company, bioMerieux SA, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Hologic Inc, Illumina Inc., Immucor Inc. (IVD Holdings Inc.), Merck KGaA, Qiagen N.V. and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report:

• How has the global transplant diagnostics market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global transplant diagnostics market?
• What are the key regional markets?
• What is the breakup of the market based on the component?
• What is the breakup of the market based on the technology?
• What is the breakup of the market based on the organ type?
• What is the breakup of the market based on the application?
• What is the breakup of the market based on the end user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global transplant diagnostics market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Transplant Diagnostics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Component

• 6.1 Instrument and Equipment
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Reagent and Consumables
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Software and Services
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Technology

• 7.1 Non-Molecular Assay
  • 7.1.1 Market Trends
  • 7.1.2 Key Segments
    • 7.1.2.1 Serological Assay
    • 7.1.2.2 Mixed Lymphocyte Culture
  • 7.1.3 Market Forecast
• 7.2 Molecular Assay
  • 7.2.1 Market Trends
  • 7.2.2 Key Segments
    • 7.2.2.1 PC-based
    • 7.2.2.2 Sequencing-based
  • 7.2.3 Market Forecast

8 Market Breakup by Organ Type

• 8.1 Kidney
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Liver
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Heart
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Lung
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Pancreas
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast
• 8.6 Others
  • 8.6.1 Market Trends
  • 8.6.2 Market Forecast

9 Market Breakup by Application

• 9.1 Pre-Transplant Diagnostics
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Post-Transplant Diagnostics
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast

10 Market Breakup by End User

• 10.1 Hospitals and Transplant Centers
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Research Laboratories and Academic Institutes
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Commercial Service Providers
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast

11 Market Breakup by Region

• 11.1 North America
  • 11.1.1 United States
    • 11.1.1.1 Market Trends
    • 11.1.1.2 Market Forecast
  • 11.1.2 Canada
    • 11.1.2.1 Market Trends
    • 11.1.2.2 Market Forecast
• 11.2 Asia-Pacific
  • 11.2.1 China
    • 11.2.1.1 Market Trends
    • 11.2.1.2 Market Forecast
  • 11.2.2 Japan
    • 11.2.2.1 Market Trends
    • 11.2.2.2 Market Forecast
  • 11.2.3 India
    • 11.2.3.1 Market Trends
    • 11.2.3.2 Market Forecast
  • 11.2.4 South Korea
    • 11.2.4.1 Market Trends
    • 11.2.4.2 Market Forecast
  • 11.2.5 Australia
    • 11.2.5.1 Market Trends
    • 11.2.5.2 Market Forecast
  • 11.2.6 Indonesia
    • 11.2.6.1 Market Trends
    • 11.2.6.2 Market Forecast
  • 11.2.7 Others
    • 11.2.7.1 Market Trends
    • 11.2.7.2 Market Forecast
• 11.3 Europe
  • 11.3.1 Germany
    • 11.3.1.1 Market Trends
    • 11.3.1.2 Market Forecast
  • 11.3.2 France
    • 11.3.2.1 Market Trends
    • 11.3.2.2 Market Forecast
  • 11.3.3 United Kingdom
    • 11.3.3.1 Market Trends
    • 11.3.3.2 Market Forecast
  • 11.3.4 Italy
    • 11.3.4.1 Market Trends
    • 11.3.4.2 Market Forecast
  • 11.3.5 Spain
    • 11.3.5.1 Market Trends
    • 11.3.5.2 Market Forecast
  • 11.3.6 Russia
    • 11.3.6.1 Market Trends
    • 11.3.6.2 Market Forecast
  • 11.3.7 Others
    • 11.3.7.1 Market Trends
    • 11.3.7.2 Market Forecast
• 11.4 Latin America
  • 11.4.1 Brazil
    • 11.4.1.1 Market Trends
    • 11.4.1.2 Market Forecast
  • 11.4.2 Mexico
    • 11.4.2.1 Market Trends
    • 11.4.2.2 Market Forecast
  • 11.4.3 Others
    • 11.4.3.1 Market Trends
    • 11.4.3.2 Market Forecast
• 11.5 Middle East and Africa
  • 11.5.1 Market Trends
  • 11.5.2 Market Breakup by Country
  • 11.5.3 Market Forecast

12 SWOT Analysis

• 12.1 Overview
• 12.2 Strengths
• 12.3 Weaknesses
• 12.4 Opportunities
• 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

• 14.1 Overview
• 14.2 Bargaining Power of Buyers
• 14.3 Bargaining Power of Suppliers
• 14.4 Degree of Competition
• 14.5 Threat of New Entrants
• 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

• 16.1 Market Structure
• 16.2 Key Players
• 16.3 Profiles of Key Players
  • 16.3.1 Abbott Laboratories
    • 16.3.1.1 Company Overview
    • 16.3.1.2 Product Portfolio
    • 16.3.1.3 Financials
    • 16.3.1.4 SWOT Analysis
  • 16.3.2 Becton Dickinson and Company
    • 16.3.2.1 Company Overview
    • 16.3.2.2 Product Portfolio
    • 16.3.2.3 Financials
    • 16.3.2.4 SWOT Analysis
  • 16.3.3 bioMerieux SA
    • 16.3.3.1 Company Overview
    • 16.3.3.2 Product Portfolio
    • 16.3.3.3 Financials
    • 16.3.3.4 SWOT Analysis
  • 16.3.4 Bio-Rad Laboratories Inc.
    • 16.3.4.1 Company Overview
    • 16.3.4.2 Product Portfolio
    • 16.3.4.3 Financials
    • 16.3.4.4 SWOT Analysis
  • 16.3.5 F. Hoffmann-La Roche AG
    • 16.3.5.1 Company Overview
    • 16.3.5.2 Product Portfolio
    • 16.3.5.3 SWOT Analysis
  • 16.3.6 Hologic Inc
    • 16.3.6.1 Company Overview
    • 16.3.6.2 Product Portfolio
    • 16.3.6.3 Financials
    • 16.3.6.4 SWOT Analysis
  • 16.3.7 Illumina Inc.
    • 16.3.7.1 Company Overview
    • 16.3.7.2 Product Portfolio
    • 16.3.7.3 Financials
    • 16.3.7.4 SWOT Analysis
  • 16.3.8 Immucor Inc. (IVD Holdings Inc.)
    • 16.3.8.1 Company Overview
    • 16.3.8.2 Product Portfolio
    • 16.3.8.3 SWOT Analysis
  • 16.3.9 Merck KGaA
    • 16.3.9.1 Company Overview
    • 16.3.9.2 Product Portfolio
    • 16.3.9.3 Financials
    • 16.3.9.4 SWOT Analysis
  • 16.3.10 Qiagen N.V.
    • 16.3.10.1 Company Overview
    • 16.3.10.2 Product Portfolio
    • 16.3.10.3 Financials
    • 16.3.10.4 SWOT Analysis
  • 16.3.11 Thermo Fisher Scientific Inc.
    • 16.3.11.1 Company Overview
    • 16.3.11.2 Product Portfolio
    • 16.3.11.3 Financials
    • 16.3.11.4 SWOT Analysis